DOCSLIB.ORG

2019 PHRI Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Our Team Research encompassing 1,500,000 participants on 6 continents in 102 countries 70 scientists, investigators and research fellows 300 100 study team staff studies led by PHRI Messages from the Leadership Contents Vital Signs 8 Ahead of the Curve 10 Entering its third decade, this joint Extraordinary science, consistently institute of McMaster University high-quality research, is happening Governance of PHRI 11 and Hamilton Health Sciences at Population Health Research Setting the COMPASS 12 embodies a strong culture of inquiry, Institute. Their innovative and Reducing Bleeding collaboration and innovation. fundamentally important projects 14 The high standards maintained are key to the future health of Silent But Deadly 16 by PHRI draw gifted researchers Canadians, and indeed to all Reversing Type 2 Diabetes 18 from around the world citizens of the world.” to Hamilton.” Halving Perioperative Risk 20 Paul O’Byrne Patrick Deane Dean & Vice-President, Brain Health 22 President and Chancellor, Faculty of Health McMaster University Sciences, Preventing Deaths After Heart Attacks 24 McMaster University PURE World 26 Dietary Dialogue 28 Global Health 30 Research into Action 32 Health Starts Early 34 The research by PHRI has improved I am proud of the impact on health Nature or Nurture? 36 clinical practice and disease of our studies and of our scientists.” prevention in Hamilton Many Minds, One Goal 38 Salim Yusuf and Canada.” Executive Director, Learning from International Experts 40 Population Health Rob MacIsaac Research Institute The Next Generation 42 President, Hamilton Health Sciences Early-Career Scientists 44 Optimized Operations 46 Our Research Community 48 Helping Those in Need 50 Our continued gratitude to David Braley for his generous donation to help fund Mission Forward 52 the David Braley Cardiac Vascular Stroke Research Institute building. 6 7 Vital Signs PHRI PAPERS WITH MORE THAN 1,000 CITATIONS HOPE Ramipril, NEJM 2000 REGULATORY APPROVALS BASED ON PHRI TRIALS RE-LY, NEJM 2009 PHRI TRIAL DRUG INDICATION INTERHEART, Lancet 2004 CURE, NEJM 2001 COMPASS Rivaroxaban Coronary Artery Disease / ACCORD, NEJM, 2008 Peripheral Artery Disease PCI-CURE, Lancet 2001 ACTIVE Clopidogrel Prevention of Vascular Events ONTARGET, NEJM 2008 in Atrial Fibrillation MICRO-HOPE, Lancet 2000 AVERROES Apixaban Prevention of Stroke in Atrial Fibrillation INTERHEART Obesity, Lancet 2005 RE-LY Dabigatran Prevention of Stroke in Atrial Fibrillation Global Burden of CVD Part 1, Circulation 2001 HOPE Albuminuria, JAMA 2001 ONTARGET / Telmisartan Prevention of Cardiovascular Disease CHARM-Preserved, Lancet 2003 TRANSCEND AVERROES, NEJM 2011 OASIS-6 Fondaparinux ST Elevation Myocardial Infarction HOPE Vitamin E, NEJM 2000 OASIS-5 Fondaparinux Unstable Angina/Non-ST Elevation INTERSTROKE, Lancet 2010 Myocardial Infarction ACTIVE-W, Lancet 2003 OASIS-4 Clopidogrel Unstable Angina/Non-ST Elevation CHARM-Added, Lancet 2003 Myocardial Infarction CHARM-Overall, Lancet 2003 DREAM Rosiglitazone, Lancet 2006 RESOLVD / Candesartan Heart Failure HOPE-2, NEJM 2006 CHARM Metoprolol CR INTERHEART Psychosocial, Lancet 2004 HOPE Ramipril Secondary Prevention POISE, Lancet 2008 HOPE Renal, Ann Int. Med 2001 PHRI IN PUBLICATIONS: 1993 THROUGH 2018 CHARM-Alternative, Lancet 2008 ONTARGET Renal, Lancer 2008 500 0 1,000 2,000 3,000 4,000 5,000 6,000 400 300 HOPE-3 was named by the New England Journal of Medicine as one of the most influential studies of 2016, concluding that heart disease could be prevented by giving healthy seniors a pill to lower their cholesterol. The article was one of the NEJM articles 200 deemed “the most meaningful in improving medical practice and patient care.” A paper on fat intake from the PURE study was number one on Altmetric in 2017, 100 and the physical activity paper related to PURE was in the top 100 in 2017. The PURE dairy paper was in the top 10 for 2018. 0 2011 8 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2012 2013 2014 2015 2016 2017 2018 9 Ahead of the Curve Governance of PHRI Our goal is to conduct research that can improve the world’s health through PHRI has two founding organizations, McMaster University, and Hamilton Health transformative discoveries. After first leading the preventive cardiology and Sciences (HHS). As a joint research institute, the Executive Director is responsible therapeutic program for seven years, Salim Yusuf founded PHRI in 1999 to broaden to a governing body comprising representatives of PHRI, McMaster and HHS. the research agenda. Key factors behind PHRI’s success include an extensive international network In addition, the International Scientific Advisory Board provides scientific and of committed collaborators and the wide range of the types of studies conducted, strategic advice. Its members include: including large and small randomized trials with various designs and large population-based epidemiologic studies in more than 100 countries. These studies • Sir Rory Collins, (Chair), University of Oxford, UK have enabled us to answer several questions rigorously. • Dr. Alan Bernstein, (Co-Chair), Canadian Institute for Advanced Research Our unique Prospective Urban and Rural Epidemiological (PURE) study involves • Dr. Robert Califf, Duke University, USA studying 200,000 participants in detail, and 500,000 with simple information, • Dr. Mark Lathrop, McGill University, Canada from more than 1,000 urban and rural communities in 26 high, middle and low • Lord Ajay Kakkar, University College London, UK income countries. PURE is investigating the impact of modernization, urbanization • Dr. Alan Lopez, University of Melbourne, Australia and globalization on health behaviours, how risk factors develop and influence • Dr. Sudha Seshadri, UT Health San Antonio, USA cardiovascular disease, diabetes, lung diseases, cancers, kidney disease, brain health and injuries. New ambitious studies document the health status of one million The board of Hamilton Health Sciences Research Institute (HHSRI) provides people in Asia. stewardship of the PHRI Research Endowment. HHSRI is comprised of: • Craig Laviolette, (Chair), VP, Siemens Canada Reach of participation • Rob MacIsaac, CEO, Hamilton Health Sciences • Paul O’Byrne, Dean and VP, Faculty of Health Sciences, McMaster University Studying health systems • Marvin Ryder, Asst. Prof., Marketing, McMaster University and environmental knowledge • Akbar Panju, Professor, Medicine, McMaster University implementation • Robert Jones, former Chair of Board, HHS Observational studies in 6 continents with 1,000 urban & rural Clinical trials in communities North America Dean, Faculty of Health Sciences, and Europe McMaster University Exploring new CEO, Hamilton Health Sciences disease pathways through genomics, proteomics, Expanding to dementia, metabolomics Hamilton Health Sciences International renal, stroke, perioperative Executive Committee Research Institute Scientific Advisory Foundational work in medicine, CV surgery, of PHRI Board (ISAB) important health-related cancer, thrombosis, (HHSRI) Board research, serving as a childhood risk factors model for similar efforts in other countries Scope of studies 10 11 Use of rivaroxaban, a new antithrombotic treatment, reduces heart attacks, strokes, amputations and death in patients with coronary artery disease or peripheral artery disease.” Setting the COMPASS – Stuart Connolly, Senior Scientific Lead The COMPASS trial, involving 26,997 COMPASS co-investigators patients with coronary artery disease Stuart Connolly, Jackie Bosch, or peripheral artery disease, showed John Eikelboom, Sonia Anand and that rivaroxaban plus aspirin lowered Salim Yusuf, were joined by stroke the risk of serious vascular events, researchers Robert Hart and including stroke, limb amputation Mike Sharma on COMPASS-MIND. and death — three of the most feared That study’s results found that complications of atherosclerotic low-dose rivaroxaban plus aspirin is vascular disease. These findings effective for primary and secondary represent major advances for patients. stroke prevention in patients with clinical atherosclerosis. • Rapid approval of rivaroxaban by regulators around the world • 602 hospitals and clinics in 33 countries 12 13 • Approvals by regulatory agencies worldwide of the use of apixaban and dabigatran for the prevention of stroke in patients with atrial fibrillation • Thrombosis and Atherosclerosis Research Institute (TaARI) • Canadian Venous Thromboembolism and Outcomes Research Network (CanVECTOR) Reducing Bleeding • COMPASS network of cardiologists, internists, hospitalists, vascular physicians and surgeons • INTERBLEED Network of Gastroenterologists In the ACTIVE-A study, Stuart Connolly and Salim Yusuf Can we prevent clots without found that giving clopidogrel plus aspirin to patients with atrial fibrillation, increasing bleeding?” for whom vitamin-K antagonist therapy – John Eikelboom, Senior Scientist was unsuitable, reduced major vascular events, especially stroke, but increased major hemorrhage. Thrombosis causes one in four deaths In the subsequent RE-LY and in Canada, and kills about 10 million AVERROES studies, Connolly, people a year globally. Antithrombotic Eikelboom and Yusuf proved that the drugs prevent and treat venous new oral anticoagulants, dabigatran thromboembolism, acute coronary and apixaban, were more effective than syndromes and stroke. Not all patients conventional anticoagulation (warfarin) benefit equally from drug treatment; or aspirin in preventing strokes
Recommended publications
  • 2015 Annual Report

    2015 Annual Report

    1 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................. 2 HISTORY OF THE GAIRDNER FOUNDATION .................................................................................... 3 MISSION ...................................................................................................................................................... 3 NATIONAL AND STUDENT OUTREACH PROGRAMS ....................................................................... 4 MESSAGE FROM THE CHAIR ............................................................................................................... 5 MESSAGE FROM THE PRESIDENT/SCIENTIFIC DIRECTOR ......................................................... 6 2015 YEAR IN REVIEW ............................................................................................................................. 7 REPORT ON 2015 OBJECTIVES ............................................................................................................ 14 THE YEAR AHEAD: OBJECTIVES FOR 2016 ..................................................................................... 16 THE GAIRDNER FOUNDATION VALUES OUR 2015 SPONSORS ................................................... 18 GOVERNANCE ......................................................................................................................................... 20 MEDICAL REVIEW PANEL 2015 .........................................................................................................
  • NCI Budget Fact Book for Fiscal Year 1996

    NCI Budget Fact Book for Fiscal Year 1996

    NCI FACT BOOK National Cancer Institute 1996 U.S. DEPARTMENT NATIONAL INSTITUTES OF HEALTH AND OF HEALTH HUMAN SERVICES The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892. TABLE OF CONTENTS Page Organization Director's Biography ........................................ 1 Former Directors of the NCI .................................. 2 National Cancer Advisory Board .............................. 3 Division Boards of Scientific Counselors ........................ 4 President's Cancer Panel .................................... 5 Executive Committee Members ............................... 5 Organization Charts: National Cancer Institute ................................... 6 Office of the Director ...................................... 7 Division of Basic Sciences .................................. 8 Division of Clinical Sciences ................................ 9 Division of Cancer Epidemiology and Genetics ................. 10 Division of Cancer Prevention and Control .................... 11 Division of Cancer Treatment, Diagnosis and Centers ............ 12 Division of
  • Ed 376 019 Title Institution Pub Date Note Available From

    Ed 376 019 Title Institution Pub Date Note Available From

    DOCUMENT RESUME ED 376 019 SE 053 531 TITLE Grants for Science Education, 1992-1993. INSTITUTION Howard Hughes Medical Inst., Chevy Chase, MD. Office of Grants and Special Programs. PUB DATE 93 NOTE 141p. AVAILABLE FROMHoward Hughes Medical Institute, Office of Grants and Special Programs, 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789. PUB TYPE Guides Non-Classroom Use (055) EDRS PRICE MF01/PC06 Plus Postage. DESCRIPTORS *Biomedicine; *Grants; Higher Education; *Research; *Science Education; Secondary Education ABSTRACT To help strengthen education in medicine, biology, and related sciences, the Howard Hughes Medical Institute (HHMI) launched a grants program in these areas in 1987. The grants support graduate, undergraduate, precollege and public science education, and fundamental biomedical research abroad. This document provides summaries of all projects receiving grants in 1992 and is also, in effect, a 1992 annual report for each Programmatic Area supported by HHMI. (ZWH) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made from the original document. *********************************************************************** 9- -.I I, .10 It vr .. * ie Ar -4",_ -7 \---(_,- 1 a Si It I 1 a a I tIt "PERMISSION TO REPRODUCETHIS U S DEPARTMENT OF EDUCATION GRANTED BY Orrice of Educahona, Research and irnomvernent MATERIAL HAS BEEN EDUCATIONAL RESOURCES INFORMATION CENTER (EPICI U ER-P,C This document has been reproduced as owed Iron the person or Organitation originating it C.1 Minor changes name been made to improve reproduction quality TO THE EDUCATIONALRESOURCES Ponis of vev, o ot),n(Ons staled .nlh'S doc 0 meal do not necessarily represent othc,a1 INFORMATION CENTER (ERIC) OE RI pc on or policy I I I a I -SET COPYAWAt'tMI 2 Copyright ©1993 by the Howard Hughes Medical Institute Office of Grants and Special Programs.
  • “Global Health Research”?

    “Global Health Research”?

    32 International Health: Feature Article Volume 3 No. 1, 2006 INTERNATIONAL HEALTH: FEATURE ARTICLE What is Canada Doing About “Global Health Research”? Vic Neufeld, MD, FRCPC ABSTRACT The worldwide investment in health research is currently about US$100 billion. Of this amount, less than 10% is targeted on the problems of societies that bear 90% of the global burden of illness. This article addresses this unac- ceptable situation in three ways: • by describing the global problem in more detail, including what is currently being done about it; • by summarizing Canada’s contribution to resolving the problem, both through federal government agencies, and through a new non-government organization: the Canadian Coalition for Global Health Research (CCGHR); • by suggesting what Canadian university students might consider doing about it. This includes getting informed, getting involved, and considering “global health” as one component of their future careers. The article concludes with the conviction that this is a remarkable moment for Canadians to play a more active role in global health—and indeed in global citizenship more broadly. WHAT IS CANADA DOING ABOUT “GLOBAL about the fact that research efforts to address this burden HEALTH RESEARCH”? appeared to be too small and ineffective. A major 2-year study was undertaken by the Independent International Commission n 2002, the worldwide investment in health research was on Health Research for Development (CHRD). The about US$100 billion. It is a startling fact that of this Commission released what has become a landmark report in Iamount, less than 10% was directed to research on problems 1990.1 Among its findings, the CHRD reported that about 93% of societies that bear 90% of the global burden of illness.
  • News Release

    News Release

    NEWS RELEASE: June 14, 2005 Health care leaders create Canada’s first national health advisory body The Canadian Academy of Health Sciences will give Government and the public comprehensive expertise and advice on health issues EDMONTON - When the President of the United States wants advice on a public health issue, he calls the United States’ National Academies. When the Prime Minister of Great Britain wants to seek similar counsel, he usually turns to the Royal Society of Britain. But when the Prime Minister of Canada wants similar advice, who does he call? Well, that’s not always entirely clear, given the more narrowly defined mandates of many Canadian organizations. Now, however, owing to a recent initiative by a group of leading health care leaders and researchers, the Prime Minister will be able to call the Canadian Academy of Health Sciences (CAHS), recently created to: • Develop informed, strategic assessments on urgent health issues; • Inform public policy on these issues; • Enhance Canada’s readiness to deal with global health issues; and, • Provide a recognized and authoritative Canadian health science voice internationally. According to one of the Academy’s key organizers, the establishment of the Academy is long over due—and all the more pressing given the potential global health threats to Canadians, most recently exemplified by the SARS threat. “Ask Canadians what they care about most, and they answer unequivocally: ‘health,’” explains University of Alberta Professor of Medicine Paul Armstrong, CAHS’s first president. “It makes sense, therefore, that Canada should have an organization that government—and Canadians—can turn to for sound, impartial advice and research on pressing health issues.” The organization will also have an international role to play, representing Canada’s interests abroad and working closely with other nations’ parallel agencies.
  • Commencement 1920-1940

    Commencement 1920-1940

    THE JOHNS HOPKINS UNIVERSITY BALTIMORE Conferring of Degrees At The Close Of The Fifty-Fifth Academic Year JUNE 9, 1931 IN THE LYRIC THEATRE AT 4 P. M. MARSHALS Professor William 0. Weyforth Chief Marshal Aids Dr. W. S. Holt Dr. E. E. Franklin Dr. R. T. Abercrombib Dr. E. C. Andrus Dr. G-. H. Evans Professor W. W. Ford Mr. M. W. Pullen Professor J. Hart USHERS James Nelson Witherell Chief Usher William Norris Cox, Jr. Albert Johnston Charles Henry Doeller, Jr. Rowland McDowell Ness Oscar Leslie Helm Kenneth Campbell Sharretts James Boyd Hoffman Edgar Skinner James Royall Tippett MUSIC The program is under the direction of Philip S. Morgan and will be presented by the Johns Hopkins Orchestra, Bart Wirtz, Conductor. The orchestra was founded in 1919 by the Johns Hopkins Musical Association, organized for the promotion of good music in the University and community, the officers of which are Philip S. Morgan, of the Johns Hopkins Alumni Association, President; Jonas Hamburger, Vice-President; Professor Frank Morley, Secretary; Ferdinand C. Smith, Executive Secretary; John B. Whitehead, Treasurer; S. Page Nelson, Assistant Treasurer. Eighty-three symphony concerts have been given, and the orchestra, which is composed chiefly of amateurs, has played on twenty-five occasions for public exercises of the University. — —— ORDER OF EXERCISES i Academic Procession March from " Tannhauser " B. Wagner II Invocation The Keverend Horace W. B. Donegan Rector of Christ Church III Address The President of the University IV " Kamenoi Ostrow " A. Rubinstein
  • Stephen Jay Gould Papers M1437

    Stephen Jay Gould Papers M1437

    http://oac.cdlib.org/findaid/ark:/13030/kt229036tr No online items Guide to the Stephen Jay Gould Papers M1437 Jenny Johnson Department of Special Collections and University Archives August 2011 ; revised 2019 Green Library 557 Escondido Mall Stanford 94305-6064 [email protected] URL: http://library.stanford.edu/spc Guide to the Stephen Jay Gould M1437 1 Papers M1437 Language of Material: English Contributing Institution: Department of Special Collections and University Archives Title: Stephen Jay Gould papers creator: Gould, Stephen Jay source: Shearer, Rhonda Roland Identifier/Call Number: M1437 Physical Description: 575 Linear Feet(958 boxes) Physical Description: 1180 computer file(s)(52 megabytes) Date (inclusive): 1868-2004 Date (bulk): bulk Abstract: This collection documents the life of noted American paleontologist, evolutionary biologist, and historian of science, Stephen Jay Gould. The papers include correspondence, juvenilia, manuscripts, subject files, teaching files, photographs, audiovisual materials, and personal and biographical materials created and compiled by Gould. Both textual and born-digital materials are represented in the collection. Preferred Citation [identification of item], Stephen Jay Gould Papers, M1437. Dept. of Special Collections, Stanford University Libraries, Stanford, Calif. Publication Rights While Special Collections is the owner of the physical and digital items, permission to examine collection materials is not an authorization to publish. These materials are made available for use
  • By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie
  • Printable List of Laureates

    Printable List of Laureates

    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
  • Prospectus for a Major Assessment: the Return on Investments in Health Research

    Prospectus for a Major Assessment: the Return on Investments in Health Research

    Prospectus for a Major Assessment: The Return on Investments in Health Research: Defining the Best Metrics Prepared by the Canadian Academy of Health Sciences May 2007 WO The Return on Investments in Canadian Health Research – The Situation Investments in health research have increased significantly across Canada over the past decade. Naturally, and justifiably, with these greater investments come increased expectations. In addition, the widening diversity of stakeholders engaged in and/or supporting health research has led to a broader range of anticipated outcomes. These expectations include: 1] better health; 2] greater life expectancy; 3] translation of research findings into improvements in quality of life; 4] informed public policy on health related issues across the full spectrum of government and private sector activity; 5] new commercial opportunities within and beyond Canadian borders; 6] increased attraction of the next generation to pursue careers in health research and the health sector; 7] a better ‘state of readiness” for the unexpected threats to health that inevitably develop in the contemporary world. In parallel with these expectations, a confluence of factors has placed intense focus on understanding what return our society receives for the investments made in health research. Some of these include: • lack of public understanding of the value of research and its applicability to current issues in health care at a time of unsurpassed concern about accessible, affordable, high quality health care in a publicly funded
  • LONG-TERM MEMBERS 25+ Years of Membership

    LONG-TERM MEMBERS 25+ Years of Membership

    LONG-TERM MEMBERS 25+ Years of Membership Stuart A. Aaronson, MD Stephen P. Ackland, MBBS Carol Aghajanian, MD Steven A. Akman, MD Icahn School of Medicine at Mount Sinai University of Newcastle Memorial Sloan Kettering Cancer Center Roper St. Francis Healthcare United States Australia United States United States Active Member Active Member Active Member Active Member 38 Years of Membership 33 Years of Membership 27 Years of Membership 35 Years of Membership Cory Abate-Shen, PhD Edward M. Acton, PhD Irina U. Agoulnik, PhD Emmanuel T. Akporiaye, PhD Columbia University Irving Medical United States Florida International University Verana Therapeutics Center Emeritus Member United States United States United States 42 Years of Membership Active Member Emeritus Member Active Member 25 Years of Membership 31 Years of Membership 26 Years of Membership David J. Adams, PhD Duke University Medical Center Imran Ahmad, PhD Ala-Eddin Al Moustafa, PhD James L. Abbruzzese, MD United States Northwestern Medicine McGill University Duke University Emeritus Member United States Canada United States 32 Years of Membership Active Member Active Member Active Member 25 Years of Membership 26 Years of Membership 32 Years of Membership Gregory P. Adams, PhD Elucida Oncology Nihal Ahmad, PhD Abdul Al Saadi, PhD Ehtesham A. Abdi, MBBS United States Univ. of Wisconsin Madison Sch. of Med. William Beaumont Hospital The Tweed Hospital Active Member & Public Health United States Australia 29 Years of Membership United States Emeritus Member Emeritus Member Active Member 52 Years of Membership 33 Years of Membership Lucile L. Adams-Campbell, PhD 25 Years of Membership Georgetown Lombardi Comprehensive Suresh K.
  • Martin-Lawrence-Friedland-Fonds.Pdf

    Martin-Lawrence-Friedland-Fonds.Pdf

    University of Toronto Archives and Record Management Services Finding Aids – Martin L. Friedland fonds Contains the following accessions: B1998-0006 (pp. 2-149) B2002-0022 (pp. 150-248) B2002-0023 (pp 249-280) B2008-0033 and B2014-0020 (pp. 281-352) To navigate to a particular accession, use the bookmarks in the PDF file University of Toronto Archives Martin L. Friedland Personal Records Finding Aid November 1998 Accession No. B1998–0006 Prepared by Martin L. Friedland With revisions by Harold Averill University of Toronto Archives Accession Number Provenance B1998-0006 Friedland, Martin L. Martin Lawrence Friedland – A biographical sketch Note: Reference should also be made to Friedland’s curriculum vitae and the address on his receiving the Molson Prize in 1995, both of which are appended to the end of the accompanying finding aid. Martin Friedland was born in Toronto in 1932. He was educated at the University of Toronto, in commerce and finance (BCom 1955) and law (LLB 1958), where he was the gold medallist in his graduating year. He continued his academic training at Cambridge University, from which he received his PhD in 1967. Dr. Friedland’s career has embraced several areas where he has utilized his knowledge of commerce and finance as well as of law. He has been a university professor and administrator, a shaper of public policy in Canada through his involvement with provincial and federal commissions, committees and task forces, and is an author of international standing. Dr. Friedland was called to the Ontario Bar in 1960. His contribution to the formation of public policy in Canada began with his earliest research, a study of gambling in Ontario (1961).